NaturalX Health Ventures launches a €100M fund targeting Series-A investments in consumer health startups, focusing on proactive solutions like sleep, gut health, and mental health in Europe.
Strategic Focus and Investment Approach
The Berlin-based venture capital firm will primarily target Series-A investments with initial funding ranging from €3-5 million, with the capability to invest up to €10 million per company [1][2]. This pioneering fund, announced on February 17, 2025, represents the first specialized investment vehicle in Europe focused exclusively on the intersection of consumer and healthcare [3]. Founded by Marvin Amberg in collaboration with Schwabe Group, a specialist in plant-based pharmaceuticals [4], naturalX has already demonstrated its commitment during an 18-month ramp-up phase through investments in promising startups including mybacs, Flow Neuroscience, Kyan Health, and Meela [1][5].
Market Opportunity and Timing
The fund’s launch comes at a crucial moment in European healthcare evolution. The consumer health space has been historically underserved by investors [3][5], despite growing evidence of market potential. The success of European healthcare unicorns like Flo and Neko Health in the past year [2] signals increasing market maturity. This transformation has been accelerated by the post-COVID-19 era, which has led to heightened health literacy and a shift toward proactive health management [2][5].
Investment Strategy and Focus Areas
NaturalX’s investment strategy targets solutions in sleep, gut health, prevention, longevity, and mental health [1][6]. The fund can act as either lead investor or co-investor, primarily focusing on European startups while maintaining flexibility for select North American investments [7]. Approximately 20% of the fund will be allocated to other healthcare-focused VC funds to build a strong ecosystem around their thesis [2].
Industry Backing and Future Outlook
The fund is backed by Schwabe Group, a pharmaceutical company with approximately €950 million in total turnover and over 4,000 employees globally [5]. Early portfolio companies have already praised naturalX’s approach, with mybacs founder Carl-Philipp von Polheim highlighting their ‘pragmatic, fast decision-making’ [6]. As the fund becomes fully operational, it is actively building its cross-European investment team [1][3], positioning itself to capitalize on the growing convergence of consumer wellness and healthcare innovation.